Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m

Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

Abstract: The invention relates to a specific composition comprising in particular at least gellan gum and phenylephrine. It also relates to a particular method for manufacturing such a composition and its uses in particular as a mydriatic ophthalmic product.

Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.

Abstract: The invention relates to a method for manufacturing a nanostructured powder comprising nanocrystalline agglomerates containing active pharmaceutical ingredient (API) in its crystalline form, said method comprising (i) Preparing a first solution comprising API and an API solvent; (ii) Mixing the first solution with a second solution comprising an API antisolvent and optionally a stabilizing agent P1 to obtain a third mixture; (iii) Evaporating the third mixture until both the API solvent and the API antisolvent are evaporated, advantageously under vacuum; characterized in that when the stabilizing agent P1 is present, the third mixture has a stabilizing agent P to API weight ratio equal or less than 5, preferably less than 2. The invention also concerns a nanostructured powder and a nanosuspension.

Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m

Abstract: The present invention relates to an optical imaging agent of formula (SIGNAL)n-SUPPORT-(L-BIOVECTOR)m, wherein: SUPPORT represents a physiologically acceptable chemical or biological substrate, with a particle size of between 1 and 100 nm, SIGNAL is a fluorophore, L is a linker of formula —C(X)—R1—Y—, with X being O, NH or S R1 being a (C1-C6)alkyl group, optionally R1 being a (C1-C6)alkyl group, optionally interrupted by 1 to 3 groups selected from —O—, —NH—, —C(O)—, —NHC(O)—, —(O)CNH—, —C(O)NH—N?C—, —N?C—, and (I), Y being NH or a —(O)CNH— group, and BIOVECTOR is a carbohydrate targeting markers of inflammation, advantageously selected from the group consisting of mannose, sialyl LewisX and derivatives thereof, n is greater than or equal to 0.5 and is less than 2, m is between 0 and 30, preferably between 1 and 30, more preferably between 5 and 20, diagnostic compositions comprising same and use thereof as a diagnostic agent (in vivo or ex vivo), or as contrast agent for image-guided surgery.

Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.

Abstract: The invention relates to a novel use of ultrafine nanoparticles as an imaging agent in a method for diagnosing a renal disorder. The invention also relates to the use of ultrafine nanoparticles as an imaging agent in methods for monitoring the therapeutic efficacy of a renal disorder treatment.

Abstract: The present invention relates to novel compounds which make it possible to transfer nucleic acids into cells. These novel compounds are lipid derivatives of polythiourea. They are useful for the in vitro, ex vivo or in vivo transfection of nucleic acids into various cell types.

Abstract: The present invention relates to novel compounds which make it possible to transfer nucleic acids into cells. These novel compounds are lipid derivatives of polythiourea. They are useful for the in vitro, ex vivo or in vivo transfection of nucleic acids into various cell types.